Literature DB >> 30517894

A Gut Feeling for Metformin.

David Z I Cherney1, Tony K T Lam2.   

Abstract

Metformin is a first-line glucose-lowering agent in patients with type 2 diabetes (T2D). Recently in Nature Medicine, Sun et al. (2018) reported that short-term metformin therapy decreases gut Bacteroides fragilis, consequently increasing glycoursodexoycholic acid (GUDCA) levels in humans. As an antagonist of FXR, GUDCA may carry therapeutic potential in the treatment of T2D.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30517894     DOI： 10.1016/j.cmet.2018.11.012

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


  4 in total

1.  Metabolic regulation by the intestinal metformin-AMPK axis.

Authors:  Song-Yang Zhang; Tony K T Lam
Journal:  Nat Commun       Date:  2022-05-23       Impact factor: 17.694

2.  miR-10b-5p Rescues Diabetes and Gastrointestinal Dysmotility.

Authors:  Rajan Singh; Se Eun Ha; Lai Wei; Byungchang Jin; Hannah Zogg; Sandra M Poudrier; Brian G Jorgensen; Chanjae Park; Charles F Ronkon; Allison Bartlett; Sung Cho; Addison Morales; Yu Heon Chung; Moon Young Lee; Jong Kun Park; Andrés Gottfried-Blackmore; Linda Nguyen; Kenton M Sanders; Seungil Ro
Journal:  Gastroenterology       Date:  2021-01-07       Impact factor: 22.682

Review 3.  Metformin and Its Benefits for Various Diseases.

Authors:  Ziquan Lv; Yajie Guo
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-16       Impact factor: 5.555

4.  Variation of Serum Uric Acid Is Associated With Gut Microbiota in Patients With Diabetes Mellitus.

Authors:  Weifeng Zhang; Ting Wang; Ruixue Guo; Wen Cui; Wei Yu; Zhihui Wang; Yumin Jiang; Minghan Jiang; Xiaojie Wang; Chao Liu; Jing Xiao; Jin Shang; Xuejun Wen; Zhanzheng Zhao
Journal:  Front Cell Infect Microbiol       Date:  2022-01-18       Impact factor: 5.293
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.